Alli set to launch chewable tablet this year in Europe
LONDON — GlaxoSmithKline has received a license extension in Europe for its popular weight-loss pill Alli.
The drug maker said it plans to sell new chewable tablets this spring, available at pharmacies throughout the United Kingdom.
Alli has been available in the United Kingdom since early 2009.
Stiefel announces OTC switch for acne washes
RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline company Stiefel has made its popular acne wash formulations available for over-the-counter use.
Stiefel will market two products that are indicated for the treatment of acne over the counter under the PanOxyl brand: PanOxyl acne creamy wash will be available in 4% BPO and 8% BPO.
A marketing campaign directed toward pharmacists and dermatologists will communicate details of the new PanOxyl 4% and 8% BPO acne creamy washes. The products will be available for shipment in May.
"Stiefel’s creamy wash formulations have been physician favorites for several years," stated Shayne Sundholm, VP of U.S. nonprescription dermatology at Stiefel. "And we are excited to be able to offer them to a larger number of consumers through the retail market."
PanOxyl 4% and 8% acne creamy washes feature a patented delivery system that includes dimethyl isosorbide, which solubilizes BPO and reduces particulate-based skin irritation and inflammation commonly experienced with conventional BPO formulations, the company stated.
Pfizer to acquire Ferrosan’s consumer healthcare business
NEW YORK — One of the world’s largest drug makers has entered a definitive agreement to purchase a Copenhagen-based consumer healthcare business.
Pfizer said Monday that it agreed to acquire from Altor 2003 Fund GP Limited Ferrosan’s consumer healthcare business, which includes a portfolio of such dietary supplements and lifestyle products as Multi-Tabs and Bifiform. Ferrosan caters to such markets as Russia, Ukraine, Poland, Turkey and many countries throughout Central and Eastern Europe.
Pfizer said the deal will help expand the distribution of its consumer healthcare brands, including Centrum and Caltrate. The company said it expects the deal to be completed in second quarter 2011.
Financial terms were not disclosed.